The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 17, 2015

Filed:

Feb. 22, 2006
Applicants:

J. Marc Simard, Baltimore, MD (US);

Mingkui Chen, Baltimore, MD (US);

Inventors:

J. Marc Simard, Baltimore, MD (US);

Mingkui Chen, Baltimore, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/18 (2006.01); A61K 31/64 (2006.01); A61K 31/435 (2006.01); A61K 31/198 (2006.01); A61K 31/415 (2006.01); A61K 31/17 (2006.01); A61K 31/00 (2006.01); A61K 31/175 (2006.01); A61K 31/365 (2006.01); A61K 31/426 (2006.01); A61K 31/4439 (2006.01); A61K 31/56 (2006.01); A61K 31/70 (2006.01); A61K 31/7048 (2006.01); B01J 19/00 (2006.01); B32B 37/12 (2006.01); C07K 14/705 (2006.01); G01N 27/447 (2006.01); G01N 33/68 (2006.01); B29L 31/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/17 (2013.01); A61K 31/00 (2013.01); A61K 31/175 (2013.01); A61K 31/365 (2013.01); A61K 31/426 (2013.01); A61K 31/4439 (2013.01); A61K 31/56 (2013.01); A61K 31/64 (2013.01); A61K 31/70 (2013.01); A61K 31/7048 (2013.01); B01J 19/0093 (2013.01); B32B 37/1292 (2013.01); C07K 14/705 (2013.01); G01N 27/44791 (2013.01); G01N 33/6872 (2013.01); B29L 2031/756 (2013.01); G01N 2500/04 (2013.01); Y10S 514/87 (2013.01);
Abstract

The present invention is directed to therapeutic compounds, treatment methods, and kits affecting the NCchannel of neural tissue, including neurons, glia and blood vessels within the nervous system, and methods of using same. The NCchannel is newly expressed in neural tissue following injury such as ischemia, and is regulated by the sulfonylurea receptor SUR1, being inhibited by sulfonylurea compounds, e.g., glibenclamide and tolbutamide, and opened by diazoxide. Antagonists of the NCchannel, including SUR1 antagonists, are useful in the prevention, diminution, and treatment of injured or diseased neural tissue, including astrocytes, neurons and capillary endothelial cells, that is due to ischemia, tissue trauma, brain swelling and increased tissue pressure, or other forms of brain or spinal cord disease or injury. Agonists of the NCchannel may be are useful in the treatment neural tissue where damage or destruction of the tissue, such as a gliotic capsule, is desired.


Find Patent Forward Citations

Loading…